6505--Buprenorphine Pre-solicitation notice
ID: 36E79726R0004Type: Presolicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/8b15468638764ddeba3d31aee3af5e5f/view
Timeline
    Description

    The Department of Veterans Affairs is seeking suppliers for Buprenorphine HCL/Naloxone HCL Sublingual Tablets, as outlined in the pre-solicitation notice VA797E26R0004. The procurement aims to establish a reliable supply source for federal healthcare programs, including the VA, DoD, IHS, and BOP, with a contract consisting of a one-year base period and four one-year option periods. These medications are critical for treating opioid dependence, and offerors must provide pricing for specific tablet strengths, comply with FDA manufacturing standards, and submit a Letter of Commitment from the manufacturer. Interested parties should contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further details, as compliance with various regulatory requirements and timely submission of quarterly sales reports will be essential for successful participation in this opportunity.

    Point(s) of Contact
    Amber.Zavala@va.govAmber Zavala
    (708) 786-5245
    amber.zavala@va.gov
    Files
    Title
    Posted
    36E79726R0004_1.docx
    The VA National Acquisition Center plans to issue an unrestricted Request for Proposal (RFP) 36E79726R0004 for Buprenorphine HCL/Naloxone HCL Tablets. This procurement aims to supply the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS) with an uninterrupted source of these medications. The contract will span one year with four optional one-year extensions. Distribution will occur through the VA’s and DOD’s Pharmaceutical Prime Vendor Programs. Offerors must specify the exact drug name and unique NDC number; glass bottles are unacceptable. The solicitation, identified by NAICS code 325412, will be electronically issued around January 5, 2026, with a tentative closing date of January 19, 2026. All updates will be available on http://www.sam.gov. The point of contact is Amber Zavala (amber.zavala@va.gov). Estimated annual requirements include 171,239 bottles of 2mg/0.5mg tablets and 251,144 bottles of 8mg/2mg tablets.
    36E79726R0004.docx
    This government solicitation, VA797E26R0004, outlines the requirements for establishing a supply source for Buprenorphine HCL/Naloxone HCL Sublingual Tablets for federal healthcare programs, including the VA, DoD, IHS, and BOP. The contract will have a one-year base period with four one-year option periods. Key requirements for offerors include providing prices for both line items (2MG/0.5MG and 8MG/2MG strength tablets) for all years, a 0.5% Cost Recovery Fee embedded in prices, and a unique 11-digit National Drug Code (NDC) for each product. Distributors must also submit a Letter of Commitment from the manufacturer. The document details packaging specifications, bar coding standards (including DSCSA compliance), and mandates FDA-approved manufacturing facilities with acceptable cGMP status. Quarterly sales reports and Cost Recovery Fee payments are required. Covered drugs must comply with 38 U.S.C. § 8126 and require an existing Master Agreement and Pharmaceutical Pricing Agreement with the VA.
    Lifecycle
    Title
    Type
    6505--Buprenorphine Pre-solicitation notice
    Solicitation
    6505--Buprenorphine Pre-solicitation notice
    Currently viewing
    Presolicitation
    Similar Opportunities
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the supply of Nicotine Polacrilex Mini Lozenges under solicitation number 36E79726R0007. This contract aims to establish a reliable source for the provision of these lozenges to various federal facilities, including those under the VA, DoD, IHS, and BOP, through Pharmaceutical Prime Vendor (PPV) Programs. The selected offeror will be required to comply with stringent requirements, including FDA product registration, adherence to packaging and barcoding standards, and maintaining acceptable cGMP status for manufacturing. Interested parties should contact Contract Specialist Billy Fong at Billy.Fong@va.gov for further details, and proposals must include pricing for a base year and four option years for both 2mg and 4mg lozenges.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    DA01--New Contract - Polypharmacy (VA-26-00018584)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for a new contract titled "Reducing Inappropriate Polypharmacy" to address medication management issues within the VA healthcare system. The procurement aims to develop and implement software solutions that will enhance program management, pilot phases, and sustainment of services, with an estimated total award amount of $47 million over a base period of six months and four one-year option periods. This initiative is critical for improving patient care and reducing the risks associated with polypharmacy among veterans. Interested parties must respond to the solicitation by January 14, 2026, at 10 AM Eastern Time, and can contact Contract Specialist Elena Juliano at elena.juliano@va.gov or 848-377-5194 for further information.
    DA01--Reducing Inappropriate Polypharmacy at the Department of Veterans Affairs
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking proposals for a software solution aimed at reducing inappropriate polypharmacy among Veterans, as outlined in the presolicitation notice for Request for Information (RFI) number 36C10B25Q0550. The objective is to identify multi-drug interactions, optimize medication regimens, and support deprescribing through sophisticated, clinically-evidenced technology that adheres to VA's IT standards and ensures secure handling of patient data. This initiative is critical for improving medication management and clinical outcomes for Veterans, with a formal Request for Proposal (RFP) to be issued via Contracting Opportunities. Interested parties must ensure full registration in the System for Award Management (SAM.gov) and submit their responses by September 15, 2025, at 3 PM Eastern Time. For inquiries, contact Contract Specialist Elena Juliano at elena.juliano@va.gov or Contracting Officer John Vardouniotis at ioannis.vardouniotis@va.gov.
    Ondansetron 4MG and 8MG
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ondansetron. This contract will establish a national supply source to provide Ondansetron HCL 4 and 8MG Tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The projected solicitation date is March of 2023.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    NATIONAL OPERATIONAL/MAILING SUPPLIES
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for operational and mailing supplies through solicitation number 36C77025R0004, aimed at supporting its seven Consolidated Mail Outpatient Pharmacy (CMOP) locations. This procurement involves establishing multiple National Single Award Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for essential items such as corrugated boxes, bubble mailers, sealing tape, and child-resistant medical pouches, ensuring compliance with stringent specifications for patient safety and product integrity. The awarded contracts will facilitate timely deliveries of these supplies, which are critical for the efficient processing and shipment of prescriptions to veterans. Interested vendors must submit their proposals, including product samples and pricing schedules in Excel format, by the extended deadline of January 15, 2026, at 5:00 PM CDT. For further inquiries, contact Kelly L Mann at kelly.mann@va.gov or Kelley Cunningham at kelley.cunningham@va.gov.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Trazodone tablets in various dosages and bottle counts. This procurement aims to secure a substantial quantity of pharmaceutical supplies essential for military and healthcare operations. Offerors are required to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries regarding the solicitation.